Xeomin vs. Botox: which is right for you?
LAST UPDATED: Jun 27, 2022
4 MIN READ
HERE'S WHAT WE'LL COVER
In the world of cosmetic medicines, when most people think about injectable treatments for treating fine lines and wrinkles, they think of Botox. But Botox isn’t the only brand on the market; others, like Xeomin, also exist. So, which is better, Botox or Xeomin?
Below, we discuss Xeomin vs. Botox, including their risks and side effects, so you can better understand which treatment may be right for you.
What are Xeomin and Botox?
Xeomin and Botox are two brands of injectable medications that contain botulinum toxin type A, which is a neurotoxin made by a bacterial species called Clostridium botulinum.
Both are approved as cosmetic treatments to address facial lines and wrinkles and to treat certain medical conditions (more on those later). As cosmetic injectables, they work by preventing nerve signals from getting to your facial muscles, thus relaxing the muscles and preventing them from working. This causes localized muscle relaxation that smooths the overlying skin, removing wrinkles (Padda, 2022).
Typically, a licensed healthcare provider like a dermatologist or plastic surgeon administers small volumes of these medications into frown lines (creases that appear between the eyebrows), forehead lines, crow’s feet (lines at the outer corners of the eyes), lines around the mouth, and other parts of the face, using a 1-inch needle (Small, 2014).
What is Xeomin?
Xeomin is the brand name for incobotulinumtoxinA injections. It’s used to treat facial lines and wrinkles, as well as certain other medical conditions. It works by blocking the nerve signals that cause muscle contractions, causing frown lines and other wrinkles to soften and relax.
What is Botox?
Botox is the brand name for onabotulinumtoxinA injections. It is referred to as Botox Cosmetic when used for these aesthetic purposes. Botox Cosmetic is used to treat facial lines and wrinkles, as well as certain medical conditions. In addition to treating frown lines, Botox Cosmetic is also approved to treat crow’s feet around the eyes and forehead lines (Satriyasa, 2019).
Botox injections work just like Xeomin by blocking the nerve signals to the facial muscles, allowing them to relax.
How are Botox and Xeomin similar?
Botox and Xeomin carry a few similarities. They work the same way on facial muscles, blocking the nerve signals that cause muscle contractions, which causes frown lines and other wrinkles to soften.
Xeomin and Botox also last around the same amount of time—three to four months—and only take a few minutes to inject. The full effects of botulinum toxin take about two weeks (Rappl, 2013).
Despite their similarities, Botox and Xeomin treatments are not interchangeable because they vary in their formulation, dosing, and clinical response. Talk to your dermatologist or plastic surgeon about which botulinum medication is best for you.
How are Xeomin and Botox different?
One significant difference between Xeomin and Botox is that Botox contains added proteins, and Xeomin doesn’t. When there are proteins, you might develop antibodies against the medication, potentially reducing its effectiveness (Frevert, 2012).
Xeomin also does not need to be refrigerated, while Botox requires refrigeration. Xeomin is also primarily used to treat frown lines, while Botox can treat other areas of the face with fine lines or wrinkles.
Xeomin vs. Botox price
If you’re getting Botox or Xeomin injections for aesthetic purposes, insurance is unlikely to cover them. According to the American Society of Plastic Surgeons (ASPS), an average Botox treatment can include 30 to 40 units and cost anywhere between $300 and $600. How many units are needed depends on the area that’s being treated.
If you’re receiving injections for a medical condition, however, your insurance may cover some of the treatment costs if the medication is FDA-approved to treat your specific condition.
Conditions treated with Xeomin and Botox
Both Xeomin and Botox Cosmetic are FDA-approved to treat fine lines and wrinkles but there are some other medical conditions that each of these medications is also approved to treat.
Xeomin is FDA-approved to treat (FDA, 2010):
Cervical dystonia, an abnormal head position accompanied by neck pain
Blepharospasm, an abnormal contraction of the eyelid muscle
Botox is FDA-approved to treat (FDA, 2011):
Upper limb spasticity
Axillary hyperhidrosis, or excessive sweating
Strabismus, or crossed eyes
Risks and side effects of Xeomin and Botox
Common side effects of both Xeomin and Botox include minor pain, swelling, bleeding, and bruising at the injection site. They may also cause (FDA, 2010; FDA, 2011):
Additional possible side effects of Botox include brow drooping, decreased eyesight, and allergic reactions (FDA, 2011).
You should report serious side effects, such as trouble breathing or swallowing, to your healthcare provider. Further, Xeomin and Botox should not be used with muscle relaxants as this can increase their effects.
Botox vs. Xeomin: which is better?
Both Xeomin and Botox work similarly, but some might prefer one over the other.
While Xeomin is slightly less expensive than Botox, Botox is approved to treat more areas of the face for fine lines and wrinkles. One study showed that the effects of Xeomin were seen a few days earlier than Botox. For both products, the treatment effect duration was longer in females than in males (Rappl, 2013).
In the end, you’ll need to discuss these medications with your dermatologist to determine which suits your needs and budget better. They can help you decide which injectable is best for you.
Comparison of Xeomin vs. Botox
We’ve given you a lot of information regarding the differences and similarities between these two medications. Here is a summary:
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Frevert, J. (2012). Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs in R & D. 10. 67-73. doi:10.2165/11584780-000000000-00000. Retrieved from https://link.springer.com/article/10.2165/11584780-000000000-00000#
GoodRx-a. (n.d.). Botox . Retrieved on June 15, 2022 from https://www.goodrx.com/botox
GoodRx-b. (n.d.). Xeomin . Retrieved on June 15, 2022 from https://www.goodrx.com/xeomin
National Institutes of Health. (NIH). (2010). XEOMIN - incobotulinumtoxina injection, powder, lyophilized, for solution. DailyMed . Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ccdc3aae-6e2d-4cd0-a51c-8375bfee9458&type=display#S1.5
Padda, I. S. & Tadi, P. (2022). Botulinum toxin. StatPearls . Retrieved on June 15, 2022 from https://www.ncbi.nlm.nih.gov/books/NBK557387/
Rappl, T., Parvizi, D., Friedl, H., et al. (2013). Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: A randomized, double-blind study. Clinical, Cosmetic, and Investigational Dermatology, 6, 211-219. doi:10.2147/CCID.S41537. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789632/
Satriyasa, B. K. (2019). Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clinical, Cosmetic and Investigational Dermatology, 12 , 223–228. doi:10.2147/CCID.S202919. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489637/
Small, R. (2014). Botulinum toxin injection for facial wrinkles. American Family Physician. 90 (3). 168-175. Retrieved from https://www.aafp.org/pubs/afp/issues/2014/0801/p168.html .
US Food and Drug Administration (FDA). (2010). Highlights of prescribing information: Xeomin. AccessData. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125360lbl.pdf
US Food and Drug Administration (FDA). (2011). Highlights of prescribing information: Botox. AccessData. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103000s5232lbl.pdf